Skip to main content

Advertisement

Table 3 HDACis used in combination in hematological malignancies

From: Histone deacetylase inhibitors: clinical implications for hematological malignancies

Drug Study Phase Disease NCT Status
vorinostat bortezomib Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma III MM NCT00773747 R
Sorafenib-Vorinostat Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) I AML MDS NCT00875745 R
Vorinostat,Bortezomib Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma I MM NCT00111813 ANR
SAHA + CHOP SAHA + CHOP in Untreated T-cell Non-Hodgkin’s Lymphoma I II NHL NCT00787527 R
Lenalidomide, Vorinostat and Dexamethasone Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL) (LenVoDex) I II PTCL NCT00972842 R
vorinostat bortezomib Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma II MM NCT00773838 R
Vorinostat CyclophosphamideEtoposide, Prednisone, Rituximab Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) II DLBCL NCT00667615 R
vorinostat bortezomib Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin’s Lymphoma II DLBCL NCT00810576 R
Vorinostat + Pegylated Liposomal Doxorubicin Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas I II Lymphoma NCT00785798 R
Vorinostat and Decitabine Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia I NHL, AML,ALL CML NCT00791011 R
AMG 655, Bortezomib, Vorinostat Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat I NHL, AML,ALL CML NCT00791011 R
Vorinostat, Azacitidine Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) II MDS NCT00948064 R
Vorinostat,Gemtuzumab,Ozogamicin,Idarubicin Cytarabine Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia II AML NCT01039363 R
Vorinostat, Melphalan, Prednisone Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients I II MM NCT00857324 R
Bortezomib and Vorinostat Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma II NHL NCT00992446 R
Vorinostat Lenalidomide, Bortezomib Dexamethasone A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma I MM NCT01038388 R
Vorinostat, Niacinamide, Etoposide] A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred II Lymphoid Malignancies NCT00691210 R
Vorinostat, Idarubicin, Cytarabine II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) II MDS AML NCT00656617 R
Vorinostat and Azacitidine Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia I II MDS AML NCT00392353 R
Vorinostat, Gemtuzumab ozogamicin, Azacitidine Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia I II AML NCT00895934 R
Vorinostat, Cytarabine, and Etoposide Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders I AML, MDS, MPN NCT00357305 R
Vorinostat, Decitabine Phase I Trial of Vorinostat (MK0683, SAHA) in Combination With Decitabine in Patients With AML or MDS. I AML MDS NCT00479232 ANR
Vorinostat, Gemtuzumab ozogamicin, Vorinostat and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia II AML NCT00673153 R
Vorinostat, Bortezomib, Doxorubicin Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma I MM NCT00744354 R
Vorinostat, Cladribine, Rituximab Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma I II MCL, CLL, NHL NCT00764517 R
Vorinostat, Rituximab, Ifosfamide, Carboplatin, Etoposide Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Primary Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma I II Lymphoma NCT00601718 R
Vorinostat, Rituximab +/- CHT Vorinostat, Rituximab, and Combination Chemotherapy In Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma I II DLBCL NCT00972478 R
Vorinostat, Fludarabine Cyclophosphamide, Rituximab Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma II B-CLL, SLL NCT00918723 R
Vorinostat Cytarabine Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007) I II MDS NCT00776503 R
Vorinostat Rituximab Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma II NHL NCT00720876 R
Bortezomib Vorinostat Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma II MCL DLBCL NCT00703664 R
Vorinostat Lenalidomide Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Persistent Multiple Myeloma. I MM NCT00729118 R
Vorinostat Lenalidomide Dexamethasone Vorinostat (MK0683, SAHA) + Revlimid + Dexamethasone in Multiple Myeloma I MM NCT00642954 ANR
Flavopiridol Vorinostat Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia I AML CML MDS NCT00278330 ANR
Bortezomib Vorinostat Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia II MDS AML NCT00818649 ANR
Vorinostat bexarotene An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients I CTCL NCT00127101 R
Dasatinib Vorinostat Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia I CML ALL NCT00816283 R
Decitabine, Vorinostat CHT Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment II CML ALL NCT00882206 R
Vorinostat Bortezomib Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (COMBOSTAT) II NHL NCT00837174 R
Panobinostat and Everolimus Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma I II MM NHL HL NCT00918333 R
Panobinostat Bortezomib Dexamethasone Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma III MM NCT01023308 R
Panobinostat LBH589 Plus I II MDS AML NCT00691 R
Decitabine Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia    938  
Panobinostat Imatinib LBH589 and Imatinib in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia I CML NCT00686218 R
Panobinostat Bortezomib Panobinostat/Velcade in Multiple Myeloma I MM NCT00891033 R
Panobinostat Everolimus Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma I II NHL NCT00967044 R
Bortezomib, Panobinostat Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma II PTCL NCT00901147 R
Panobinostat,, bortezomib, dexamethasone Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (PANORAMA II) II MM NCT01083602 R
Panobinostat, Ara-C,Mitoxantrone A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia I AML NCT01055483 R
Panobinostat 5-Azacytidine Dose-Finding Study of Panobinostat Given in Combination With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) I MDS, CMML, AML NCT00946647 R
Melphalan Panobinostat Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma I II MM NCT00743288 R
Panobinostat +/- EPO BH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk MDS (GEPARD) II MDS NCT01034657 R
Panobinostat Decitabine LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia I II AML MDS NCT00691938 R
GIVINOSTAT (ITF2357) + hydroxyurea Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV) II PV JAK2 + NCT00928707 R
5 azacytidine - Valproïc acid- Retinoic acid 5-Azacytidine Valproic Acid and ATRA in AML and High Risk MDS II AML MDS NCT00339196 R
Entinostat Azacitidine MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia I MDS CMML AML NCT00101179 ANR
Entinostat, GM-CSF A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies II MDS NCT00466115 R
Entinostat ± Azacitidine Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia II MDS AML CMML NCT00313586 R
Entinostat, GM-CSF MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia II AML ALL MDS MPN NCT00462605 R
Mocetinostat Azacitidine Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) II AML MDS NCT00666497 C
Mocetinostat Azacitidine MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma II NHL HL NCT00543582 C
Mocetinostat Azacitidine A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia I II AML MDS NCT00324220 R
Belinostat Bortezomib A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma II MM NCT00431340 ANR
Belinostat Dexametasone Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma II MM NCT00131261 C
Belinostat and Azacitidine PXD101 and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases I Hematological neoplasms NCT00351975 R
Romidepsin Bortezomib Dexametasone A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma I II MM NCT00431990 R
Romidepsin Fludarabine Rituximab R901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin’s Lymphoma I II NHL NCT00079443 C
Cytarabine, all-trans retinoic acid, valproic acid Combined Therapy With Valproic Acid, All-trans Retinoic Acid (ATRA) and Cytarabine in Human Acute Myelogenous Leukemia (AML) I II AML NCT00995332 R
  1. R recruiting, C completed, ANR active, not recruiting; MDS myelodysplastic syndromes, AML acute myelogenous leukemia, T/B-ALL acute lymphoblastic leukemia (T- or B-cell), HD Hodgkin disease, NHL non-Hodgkin lymphoma, DLBL diffuse large B-cell lymphoma, FL follicular lymphoma, CTCL cutaneous T-cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocyte lymphoma, MCL mantle cell lymphoma, PTCL peripheral T-cell lymphoma, CML chronic myelogenous leukemia, MPN myeloproliferative neoplasm, WM Waldenstrom macroglobulinemia, MM multiple myeloma, PV policytemia vera, ET essential thombocytemia, MMM myelofibrosis with myeloid metaplasia